Montelukast

Patient with known aspirin sensitivity (continue avoidance of aspirin or NSAIDs during treatment with montelukast). Not indicated for the treatment of acute asthma attacks, including status asthmaticus. Not recommended as monotherapy in patients with moderate persistent asthma. Avoid abrupt substitution to inhaled or oral corticosteroids. Children. Pregnancy and lactation. Monitoring Parameters Monitor for neuropsychiatric symptoms, including changes in behaviour and suicidal thoughts.

Significant: Neuropsychiatric events (e.g. agitation, depression, hallucinations, suicidal thoughts and behaviour, dream abnormalities, aggressive behaviour or hostility, anxiety, disorientation, disturbance in attention, dysphemia, insomnia, irritability, memory impairment, obsessive-compulsive symptoms, restlessness, somnambulism, tic, tremor). Rarely, systemic eosinophilia (sometimes presenting with clinical features of vasculitis consistent with Churg-Strauss syndrome). Blood and lymphatic system disorders: Rarely, increased bleeding tendency, thrombocytopenia. Cardiac disorders: Rarely, palpitations. Ear and labyrinth disorders: Otitis media. Gastrointestinal disorders: Abdominal pain, diarrhoea, nausea, vomiting, thirst, dry mouth, dyspepsia. General disorders and administration site conditions: Pyrexia, asthenia, malaise, oedema. Immune system disorders: Hypersensitivity reactions including anaphylaxis. Investigations: Elevated ALT/AST levels. Musculoskeletal and connective tissue disorders: Myalgia, arthralgia, muscle cramps. Nervous system disorders: Headache, dizziness, drowsiness, paraesthesia, hypoaesthesia, seizure. Respiratory, thoracic and mediastinal disorders: Upper respiratory tract infection, pharyngitis, cough, influenza, rhinorrhea, sinusitis, epistaxis. Skin and subcutaneous tissue disorders: Rash, pruritus, urticaria, bruising.

Decreased plasma concentration with CYP inducers (e.g. phenobarbital, phenytoin, rifampicin). Increased systemic exposure with gemfibrozil.

Antiasthmatic & COPD Preparations / Antihistamines & Antiallergics

R03DC03 - montelukast ; Belongs to the class of leukotriene receptor antagonists. Used in the systemic treatment of obstructive airway diseases.